DiaPark is developing an early diagnostic test system for Parkinson's disease using immunological and genetic chips, as well as electrophysiological tests. The system aims to detect Parkinson's disease several years before symptoms appear to enable early treatment. DiaPark costs $150 per patient compared to $6,000 for current PET scans, making it economically feasible for mass diagnostics. The team is seeking $2 million in funding for clinical trials, product certification, and marketing to bring the system to market globally.